TY - JOUR
T1 - Female Sexual Dysfunction—Medical and Psychological Treatments, Committee 14
AU - Kingsberg, Sheryl A.
AU - Althof, Stanley
AU - Simon, James A.
AU - Bradford, Andrea
AU - Bitzer, Johannes
AU - Carvalho, Joana
AU - Flynn, Kathryn E.
AU - Nappi, Rossella E.
AU - Reese, Jennifer B.
AU - Rezaee, Roya L.
AU - Schover, Leslie
AU - Shifrin, Jan L.
N1 - Publisher Copyright:
© 2017 International Society for Sexual Medicine
PY - 2017/12
Y1 - 2017/12
N2 - Introduction Since the millennium we have witnessed significant strides in the science and treatment of female sexual dysfunction (FSD). This forward progress has included (i) the development of new theoretical models to describe healthy and dysfunctional sexual responses in women; (ii) alternative classification strategies of female sexual disorders; (iii) major advances in brain, hormonal, psychological, and interpersonal research focusing on etiologic factors and treatment approaches; (iv) strong and effective public advocacy for FSD; and (v) greater educational awareness of the impact of FSD on the woman and her partner. Aims To review the literature and describe the best practices for assessing and treating women with hypoactive sexual desire disorder, female sexual arousal disorder, and female orgasmic disorders. Methods The committee undertook a comprehensive review of the literature and discussion among themselves to determine the best assessment and treatment methods. Results Using a biopsychosocial lens, the committee presents recommendations (with levels of evidence) for assessment and treatment of hypoactive sexual desire disorder, female sexual arousal disorder, and female orgasmic disorders. Conclusion The numerous significant strides in FSD that have occurred since the previous International Consultation of Sexual Medicine publications are reviewed in this article. Although evidence supports an integrated biopsychosocial approach to assessment and treatment of these disorders, the biological and psychological factors are artificially separated for review purposes. We recognize that best outcomes are achieved when all relevant factors are identified and addressed by the clinician and patient working together in concert (the sum is greater than the whole of its parts). Kingsberg SA, Althof S, Simon JA, et al. Female Sexual Dysfunction—Medical and Psychological Treatments, Committee 14. J Sex Med 2017;14:1463–1491.
AB - Introduction Since the millennium we have witnessed significant strides in the science and treatment of female sexual dysfunction (FSD). This forward progress has included (i) the development of new theoretical models to describe healthy and dysfunctional sexual responses in women; (ii) alternative classification strategies of female sexual disorders; (iii) major advances in brain, hormonal, psychological, and interpersonal research focusing on etiologic factors and treatment approaches; (iv) strong and effective public advocacy for FSD; and (v) greater educational awareness of the impact of FSD on the woman and her partner. Aims To review the literature and describe the best practices for assessing and treating women with hypoactive sexual desire disorder, female sexual arousal disorder, and female orgasmic disorders. Methods The committee undertook a comprehensive review of the literature and discussion among themselves to determine the best assessment and treatment methods. Results Using a biopsychosocial lens, the committee presents recommendations (with levels of evidence) for assessment and treatment of hypoactive sexual desire disorder, female sexual arousal disorder, and female orgasmic disorders. Conclusion The numerous significant strides in FSD that have occurred since the previous International Consultation of Sexual Medicine publications are reviewed in this article. Although evidence supports an integrated biopsychosocial approach to assessment and treatment of these disorders, the biological and psychological factors are artificially separated for review purposes. We recognize that best outcomes are achieved when all relevant factors are identified and addressed by the clinician and patient working together in concert (the sum is greater than the whole of its parts). Kingsberg SA, Althof S, Simon JA, et al. Female Sexual Dysfunction—Medical and Psychological Treatments, Committee 14. J Sex Med 2017;14:1463–1491.
KW - Female Orgasmic Dysfunction
KW - Female Sexual Arousal Disorder
KW - Female Sexual Dysfunction
KW - Hypoactive Sexual Desire Disorder
KW - Persistent Genital Arousal Disorder
UR - http://www.scopus.com/inward/record.url?scp=85036561294&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000424026800001&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1016/j.jsxm.2017.05.018
DO - 10.1016/j.jsxm.2017.05.018
M3 - Article
C2 - 29198504
SN - 1743-6095
VL - 14
SP - 1463
EP - 1491
JO - Journal of Sexual Medicine
JF - Journal of Sexual Medicine
IS - 12
ER -